Literature DB >> 10094256

Neurological complications of neurofibromatosis type 1 in adulthood.

A Créange1, J Zeller, S Rostaing-Rigattieri, P Brugières, J D Degos, J Revuz, P Wolkenstein.   

Abstract

Neurofibromatosis type 1 (NF1) is a genetic disease with a wide range of neurological manifestations. To examine these, and to evaluate neurological morbidity in adulthood of patients with NF1, we studied a hospital-based series of 158 patients that included 138 adult patients aged >18 years and 20 children. NF1 evaluation included a multidisciplinary clinical and a clinically oriented radiological investigation. Neurological events occurring during childhood (in both children and adults of the series) and adulthood were recorded. One or several neurological manifestations have been observed in 55% of patients (adults and children) (n = 87). These included: headache (28 patients); hydrocephalus (7); epilepsy (5); lacunar stroke (1); white matter disease (1); intraspinal neurofibroma (3); facial palsy (1); radiculopathy (5); and polyneuropathy (2). Tumours included: optic pathway tumours (20); meningioma (2); cerebral glioma (3); and malignant peripheral nerve sheath tumours (6). Life-threatening complications were observed in five adults and included four malignant peripheral nerve sheath tumours and one meningioma. Pain was the leading symptom in 11 adults and was related to malignant peripheral nerve sheath tumours, complications of intraspinal neurofibromas, subcutaneous neurofibromas and peripheral nerve neurofibromas. NF1 in adults was not associated with other disabling or life-threatening neurological complications. Symptomatic optic pathway tumours, cerebral gliomas, symptomatic aqueductal stenosis and spinal compression due to intraspinal NF were observed exclusively during childhood. In this series, the predominant neurological features of adults with NF1 were chronic pain and malignant peripheral nerve sheath tumours.

Entities:  

Mesh:

Year:  1999        PMID: 10094256     DOI: 10.1093/brain/122.3.473

Source DB:  PubMed          Journal:  Brain        ISSN: 0006-8950            Impact factor:   13.501


  60 in total

1.  Giant plexiform neurofibroma with hemorrhage in cranio-maxillofacial region as depicted on CT and MRI.

Authors:  Y Feng; Zhi-Gang Yang; T Chen; Q Wang; W Deng
Journal:  Eur J Med Res       Date:  2010-02-26       Impact factor: 2.175

2.  Diagnosis, management, and complications of glomus tumours of the digits in neurofibromatosis type 1.

Authors:  Douglas R Stewart; Jennifer L Sloan; Lawrence Yao; Andrew J Mannes; Armin Moshyedi; Chyi-Chia Richard Lee; Raf Sciot; Luc De Smet; Victor-Felix Mautner; Eric Legius
Journal:  J Med Genet       Date:  2010-06-07       Impact factor: 6.318

3.  Von recklinghausens disease: a series of four cases with variable expression.

Authors:  K P Arun; P Thomas Joseph; H P Jaishankar; M S Abhinethra
Journal:  J Maxillofac Oral Surg       Date:  2013-02-07

4.  CRMP2-Neurofibromin Interface Drives NF1-related Pain.

Authors:  Aubin Moutal; Li Sun; Xiaofang Yang; Wennan Li; Song Cai; Shizhen Luo; Rajesh Khanna
Journal:  Neuroscience       Date:  2018-04-12       Impact factor: 3.590

Review 5.  Sensitization of Ion Channels Contributes to Central and Peripheral Dysfunction in Neurofibromatosis Type 1.

Authors:  Aubin Moutal; Erik T Dustrude; Rajesh Khanna
Journal:  Mol Neurobiol       Date:  2016-05-11       Impact factor: 5.590

6.  Neurofibromatosis type 1 and infantile spasms.

Authors:  Martino Ruggieri; Paola Iannetti; Maurizio Clementi; Agata Polizzi; Gemma Incorpora; Alberto Spalice; Piero Pavone; Andrea Domenico Praticò; Maurizio Elia; Anna Lia Gabriele; Romano Tenconi; Lorenzo Pavone
Journal:  Childs Nerv Syst       Date:  2008-09-19       Impact factor: 1.475

7.  Perinatal epidermal growth factor receptor blockade prevents peripheral nerve disruption in a mouse model reminiscent of benign world health organization grade I neurofibroma.

Authors:  Jianqiang Wu; Jason T Crimmins; Kelly R Monk; Jon P Williams; Maureen E Fitzgerald; Susan Tedesco; Nancy Ratner
Journal:  Am J Pathol       Date:  2006-05       Impact factor: 4.307

8.  Treatment of neurofibromatosis type 1.

Authors:  Caterina Sabatini; Donatella Milani; Francesca Menni; Gianluca Tadini; Susanna Esposito
Journal:  Curr Treat Options Neurol       Date:  2015-06       Impact factor: 3.598

9.  Patient-reported outcomes of pain and physical functioning in neurofibromatosis clinical trials.

Authors:  Pamela L Wolters; Staci Martin; Vanessa L Merker; James H Tonsgard; Sondra E Solomon; Andrea Baldwin; Amanda L Bergner; Karin Walsh; Heather L Thompson; Kathy L Gardner; Cynthia M Hingtgen; Elizabeth Schorry; William N Dudley; Barbara Franklin
Journal:  Neurology       Date:  2016-08-16       Impact factor: 9.910

10.  Nutraceuticals safety and efficacy in migraine without aura in a population of children affected by neurofibromatosis type I.

Authors:  Marco Carotenuto; Maria Esposito
Journal:  Neurol Sci       Date:  2013-03-27       Impact factor: 3.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.